Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thyroid hormone receptor, beta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | photoreceptor-specific nuclear receptor | thyroid hormone receptor, beta | 461 aa | 414 aa | 24.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0294 | 1 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0294 | 1 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0294 | 1 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0294 | 1 | 1 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0294 | 1 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0294 | 1 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0294 | 1 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0294 | 1 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0294 | 1 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0294 | 1 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0294 | 1 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0294 | 1 | 1 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0294 | 1 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.0857 | 0.0857 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0294 | 1 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0294 | 1 | 1 |
Plasmodium vivax | RNA helicase-1, putative | 0.0294 | 1 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0294 | 1 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0294 | 1 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0294 | 1 | 0.5 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0164 | 0.0857 | 0.0857 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.0857 | 0.0857 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0294 | 1 | 1 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0294 | 1 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0294 | 1 | 1 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0294 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.3548 um | PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.